Pharmacogenomics

Week of 13 October 2026

7 articles

Geno'X Veille — genox-veille.fr

Key takeaways this week

►CYP2C19 — mild to moderate stroke (n = 741): no genotype × dual antiplatelet therapy interaction on 90-day outcome.
►DPYD — in 203 patients, DPD activity and plasma metabolites correlate too weakly to replace genotyping.
►CYP2B6 — added to the CYP2C19 phenotype, it improves the explanation of sertraline concentrations and antidepressant switching (n = 1,070).
►CYP2D6 — the J1 haplotype (rs2267439) does not improve prediction of risperidone metabolism in 125 Nigerian patients.
►CYP3A5 — doubled starting dose of extended-release tacrolimus: target reached in 13 versus 25 days in normal metabolizers.
►DPYD — 26 rare Japanese variants characterised in vitro, 5 with reduced or abolished activity, awaiting clinical validation.

Category:

Filters··Min. score

7 articles of 7

Sort

Dual Antiplatelet Therapy in Acute Ischemic Stroke: A 2-Time-Window Study of CYP2C19 Genotypes and Functional Outcomes.

Mild to moderate acute ischemic stroke on dual antiplatelet therapy

J Am Heart Assoc 2026· SepRead

Dihydropyrimidine Dehydrogenase Genotype-Phenotype Correlations in Plasma and Peripheral Blood Mononuclear Cells.

Severe 5-fluorouracil toxicity due to DPD deficiency

OncologyAdverse reactionPreemptive genotyping

Clin Pharmacol Ther 2026· OctRead

Impact of combined CYP2C19/CYP2B6 phenotypes on sertraline dose-normalized concentration and antidepressant switching incidence: A retrospective cohort study in Chinese Han population.

Major depressive disorder treated with sertraline

Prog Neuropsychopharmacol Biol Psychiatry 2026· OctRead

Distribution of the J1 haplotype variant rs2267439 across CYP2D6 diplotypes and its impact on risperidone metabolism.

Risperidone treatment and CYP2D6 phenotype prediction

Pharmacogenet Genomics 2026· OctRead

Genotype-Guided Dosing Improves Attainment of Therapeutic Troughs in CYP3A5 Normal Metabolizers After Kidney Transplantation.

Kidney transplantation on extended-release tacrolimus

Dose recommendationPreemptive genotyping

Am J Health Syst Pharm 2026· OctRead

Using multi-trait polygenic scores to predict lithium responsiveness in patients with bipolar disorder.

Bipolar disorder treated with lithium

Br J Psychiatry 2026· OctRead

Functional characterization of rare DPYD variants identified in 8,380 Japanese individuals: implications for 5-fluorouracil metabolism.

DPD deficiency and fluoropyrimidine toxicity

OncologyRecurrent variant

Drug Metab Dispos 2026· SepRead

References and sources

CYP2C19 — Mild to moderate acute ischemic stroke on dual antiplatelet therapy. J Am Heart Assoc 2026. PMID 42808443. Score 7/10. https://pubmed.ncbi.nlm.nih.gov/42808443/
DPYD — Severe 5-fluorouracil toxicity due to DPD deficiency. Clin Pharmacol Ther 2026. PMID 42839587. Score 7/10. https://pubmed.ncbi.nlm.nih.gov/42839587/
CYP2C19 — Major depressive disorder treated with sertraline. Prog Neuropsychopharmacol Biol Psychiatry 2026. PMID 42858801. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42858801/
CYP2D6 — Risperidone treatment and CYP2D6 phenotype prediction. Pharmacogenet Genomics 2026. PMID 42842892. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42842892/
CYP3A5 — Kidney transplantation on extended-release tacrolimus. Am J Health Syst Pharm 2026. PMID 42862104. Score 5/10. https://pubmed.ncbi.nlm.nih.gov/42862104/
DPYD — DPD deficiency and fluoropyrimidine toxicity. Drug Metab Dispos 2026. PMID 42858610. Score 4/10. https://pubmed.ncbi.nlm.nih.gov/42858610/
Bipolar disorder treated with lithium. Br J Psychiatry 2026. PMID 42841250. Score 5/10. https://pubmed.ncbi.nlm.nih.gov/42841250/